In datasets derived from the Affymetrix gene chips (Fig. 2A), higher expression of BTN3A1 was associated with better prognosis in breast cancer, ovarian cancer, gastric cancer, and NSCLC. This evidence concerns the gene BTN3A1 and ovarian cancer.